Clinical Trials · NCT01126580
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 807
- Start date
- May 2010
- Locations
- 91 sites, 19 countries
- Primary endpoint
- Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)